Trial reportLeukemia2020
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Abstract readLetterMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.The New England journal of medicine · 2025Trial
- Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL.Hematology. American Society of Hematology. Education Program · 2025Review
- Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group.Clinical journal of oncology nursing · 2025Article
- Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead.Cureus · 2024Review
- Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.Wiener klinische Wochenschrift · 2024Article
- Review
- One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.Journal of cancer research and clinical oncology · 2023Article
- Hypersensitivity Reactions to NativeHemaSphere · 2023Article
- Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Article
- Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia.Journal of the National Cancer Institute · 2022Article
- Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports).Therapeutic advances in hematology · 2022Article
- Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2.Pediatric blood & cancer · 2021Article
- Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.Cancer research and treatment · 2021Article
- Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy.Frontiers in pediatrics · 2021Review
- Self- and Parent-Reported Psychological Symptoms in Young Cancer Survivors and Control Peers: Results from a Clinical Center.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Andishe Attarbaschi *Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. andishe.attarbaschi@stanna.at.
Georg Mann *Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Martin Zimmermann *Department of Pediatric Hematology and Oncology, Children's Hospital, Medical School Hannover, Hannover, Germany.
Peter BaderDepartment of Children and Adolescent Medicine, Children's Hospital, Goethe University, Frankfurt, Germany.
Elena BarisonePediatric Onco-Hematology, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy.
Giuseppe BassoItalian Institute for Genomic Medicine, Turin, Italy.
Andrea BiondiPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
Gunnar CarioDepartment of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Gianni CazzanigaPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.ORCID http://orcid.org/0000-0003-2955-4528
Antonella ColombiniPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
Christian FlothoDepartment of Pediatric Hematology and Oncology, Children's Hospital, Albert Ludwigs University, Freiburg, Germany.
Michaela KuhlenUniversity Children's Hospital Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.ORCID http://orcid.org/0000-0003-4577-0503
Peter LangDepartment of Pediatric Hematology and Oncology, Children's Hospital, Eberhard Karls University, Tübingen, Germany.
Melchior LautenDepartment of Pediatric and Adolescent Medicine, Children's Hospital, University of Lübeck, Lübeck, Germany.
Christin LinderkampDepartment of Pediatric Hematology and Oncology, Children's Hospital, Medical School Hannover, Hannover, Germany.
Franco LocatelliDepartment of Pediatric Hematology-Oncology, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
Luca Lo NigroCenter of Pediatric Hematology Oncology, Azienda Policlinico-OVE, Catania, Italy.
Anja MörickeDepartment of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Felix NiggliDepartment of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.
Renate Panzer-GrümayerDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Rosanna ParasoleDepartment of Pediatric Hemato-Oncology, A.O.R.N. Santobono-Pausilipon, Naples, Italy.
Christina PetersDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0369-8515
Maria Caterina PuttiDepartment of Woman and Child Health, Clinic of Pediatric Haematology-Oncology, University of Padova, Padova, Italy.
Carmelo RizzariPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
Meinolf SuttorpDepartment of Pediatrics, Pediatric Hemato-Oncology Unit, Children's Hospital, University Hospital "Carl Gustav Carus", Dresden, Germany.
Maria Grazia ValsecchiCenter of Biostatistics for Clinical Epidemiology, Department of Health Science, University of Milano-Bicocca, Milano, Italy.
Valentino Conter *Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
Martin Schrappe *Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseChildChild, PreschoolCyclophosphamideCytarabineDaunorubicinFemaleHumansInfantMaleMercaptopurineMethotrexatePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoneAsparaginaseCyclophosphamideCytarabineDaunorubicinMercaptopurineMethotrexatePrednisoneVincristine
Identifiers
PMID
31806872What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.